Login to Your Account



Clinic Roundup


Tuesday, January 24, 2012
• Enlivex Therapeutics Ltd., of Jerusalem, said it completed patient enrollment in the Phase I/II trial of its drug under development for autoimmune diseases. The trial was conducted on bone marrow transplant patients, who often acquire graft-vs.-host disease (GVHD), but the company said results are relevant to other immune system diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription